# CellRX Indexation Remediation — Validation Record

**Completed:** August 21, 2026  
**Scope:** Crawled-but-not-indexed remediation for the public CellRX website, with emphasis on the two priority medical-education articles, the XML sitemap, canonical consistency, and direct crawler responses.

## Implemented corrections

| Area | Correction | Expected indexing effect |
|---|---|---|
| Priority article metadata | Replaced generic metadata with unique, subject-matched titles, descriptions, canonical URLs, and article schema for the IV-therapy and chain-of-custody articles. | Makes the crawler-facing topic and visible H1 consistent. |
| Patient-education quality | Added visible regulatory context, source links, reviewer context, and evidence-aware language to the two priority articles. | Improves clarity and trust signals for health-related content. |
| Canonical linking | Blog cards and related-reading links now point to trailing-slash canonical article URLs. | Removes a recurring internal signal toward redirecting URL variants. |
| FDA disclaimer | Changed the utility page to `noindex, follow` for both `robots` and `googlebot`; removed it from the XML sitemap. | Preserves the page for users and link discovery without asking Google to index a low-value legal utility page. |
| Sitemap hygiene | Removed six unpublished future article URLs and all future-dated publication signals. | Prevents crawlers from spending attention on pages that are not yet publishable. |
| Unknown routes | Corrected the production wildcard handler to use the original request URL. Removed and arbitrary unknown article URLs now return a `404` page with `noindex, follow` rather than an indexable homepage shell. | Prevents accidental soft-404 / duplicated-homepage behavior. |

## Validation results

| Check | Result |
|---|---|
| Production build | Passed with `pnpm build`; static SEO export completed for 22 public routes plus 404 and legacy redirect. |
| Priority article static output | Passed: unique title, trailing-slash canonical URL, FDA citation, and crawler-visible fallback content are present. |
| FDA utility page | Passed: direct rendered HTML carries `robots` and `googlebot` values of `noindex, follow`. |
| XML sitemap | Passed: FDA disclaimer, six unpublished planned articles, and future September/October dates are absent. |
| Direct HTTP responses | Passed: priority article `200`; FDA disclaimer `200`; removed future article `404` with a `noindex, follow` response. |
| Visual review | Passed: the rendered IV article presents the revised H1, byline, evidence-aware copy, and linked references in a readable clinical editorial layout. |

## Limits and required next steps

This work corrects public technical and content signals; it does not guarantee that Google will index any URL. After the remediation is published, submit the updated sitemap in Search Console and inspect the two priority canonical URLs. Request indexing only after the live domain returns the verified new content. Google’s decision can still take time and considers broader quality and duplication signals.[1] [2]

The site’s regular production build passed. The standalone `tsc --noEmit` process was terminated by the local sandbox before it completed, so the build and direct HTTP checks are the recorded validation basis.

## References

[1] [Google Search Essentials](https://developers.google.com/search/docs/essentials)  
[2] [Google: Creating helpful, reliable, people-first content](https://developers.google.com/search/docs/fundamentals/creating-helpful-content)  
[3] [FDA: Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes)  
[4] [FDA: Important Patient and Consumer Information About Regenerative Medicine Therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies)

